Cold Chain Technologies (CCT) has reported data from a key vaccine distribution project which ultimately helped to eliminate temperature excursions, reduce reships by 84%, and prevent 2 million pounds (907,000kgs) of waste to landfill.
Touchlight’s cell-free, enzymatic dbDNA manufacturing platform underpins the NEOVACC Phase I trial led by The Clatterbridge Cancer Centre and the University of Liverpool.
SGS has achieved a "breakthrough" in infectious disease research with the launch of a novel Respiratory Syncytial Virus (RSV) A-strain challenge agent with proven infectivity in preclinical and clinical stage.
Mitra Mosharraf, PhD, M.B.A., CSO, HTD Biosystems will do a talk on "Strategies for Manufacturing and Analysis of Lipid-Based Nanomedicines and Vaccines" at PharmSci 360, on 10th November.
Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford.
Vicebio, a biopharmaceutical company developing vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi.
A large-scale international study involving researchers from the Drug Safety Research Unit (DSRU), UK, highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain-Barré syndrome (GBS).
Osivax has announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate.
After Lonza announced the collaboration with Ethris to develop spray-dried mRNA vaccines for Respiratory Disease Prevention, EPM spoke to Carsten Rudolph, co-founder, Ethris and Kim Shepard, director of advanced drug delivery at Lonza to learn more.
Infinitopes has announced that the UK Medicines and Healthcare products Regulatory Agency has granted Clinical Trial Application (CTA) approval for the first-in-human Phase I/IIa clinical trial of ITOP1, the company’s ‘off-the-shelf’ cancer vaccine.
